Golden-Mason Lucy, Palmer Brent, Klarquist Jared, Mengshol John A, Castelblanco Nicole, Rosen Hugo R
Division of Gastroenterology/Hepatology, Hepatitis C Center, University of Colorado Health Sciences Center and National Jewish Hospital, Denver, CO 80262, USA.
J Virol. 2007 Sep;81(17):9249-58. doi: 10.1128/JVI.00409-07. Epub 2007 Jun 13.
Infection with hepatitis C virus (HCV) is associated with persistence in the majority of individuals. We demonstrate here that the inhibitory molecule programmed death-1 (PD-1) is significantly upregulated on total and HCV-specific CD8(+) cytotoxic T lymphocytes (CTLs) in the peripheral blood and livers of patients with chronic infection compared to subjects with spontaneous HCV resolution, patients with nonviral liver disease, and normal controls. PD-1 expression on cytomegalovirus-specific CTLs also varies according to HCV status and is highest in patients with chronic infection. HCV-specific CTLs that are PD-1(high) express higher levels of the senescence marker CD57 than PD-1(low) CTLs, and CD57 expression is greater in chronic than in resolved infection. In vitro blockade of PD-1 by monoclonal antibodies specific to its ligands (PD-L1 and PD-L2) results in restoration of functional competence (proliferation and gamma interferon and interleukin-2 secretion) of HCV-specific CTLs, including those residing in the liver. This reversal of CTL exhaustion is evident even in individuals who lack HCV-specific CD4(+) T-cell help. Our data indicate that the PD-1/PD-L pathway is critical in persistent HCV infection in humans and represents a potential novel target for restoring function of exhausted HCV-specific CTLs.
丙型肝炎病毒(HCV)感染在大多数个体中会持续存在。我们在此证明,与自发清除HCV的受试者、非病毒性肝病患者及正常对照相比,慢性感染患者外周血和肝脏中总的及HCV特异性CD8(+)细胞毒性T淋巴细胞(CTL)上的抑制分子程序性死亡-1(PD-1)显著上调。巨细胞病毒特异性CTL上的PD-1表达也因HCV状态而异,在慢性感染患者中最高。PD-1(高表达)的HCV特异性CTL比PD-1(低表达)的CTL表达更高水平的衰老标志物CD57,且慢性感染中CD57的表达高于已清除感染。用针对其配体(PD-L1和PD-L2)的单克隆抗体在体外阻断PD-1可恢复HCV特异性CTL的功能能力(增殖、γ干扰素和白细胞介素-2分泌),包括那些存在于肝脏中的CTL。即使在缺乏HCV特异性CD4(+) T细胞辅助的个体中,CTL耗竭的这种逆转也很明显。我们的数据表明,PD-1/PD-L途径在人类持续性HCV感染中至关重要,并且是恢复耗竭的HCV特异性CTL功能的潜在新靶点。